SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been linked with diabetic ketoacidosis (DKA). However, characteristics of "at-risk" patients are less well described. Clinical cases were collected from South Australia between December 2015 and March 2017. Key issues identified were t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2018-04, Vol.41 (4), p.e47-e49
Hauptverfasser:	Meyer, Emily J, Gabb, Genevieve, Jesudason, David
Format:	Artikel
Sprache:	eng
Schlagworte:	Diabetes Diabetes mellitus Glucose Ketoacidosis Medical personnel Medical treatment Patients Physicians Sodium
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	e49
container_issue	4
container_start_page	e47
container_title	Diabetes care
container_volume	41
creator	Meyer, Emily J Gabb, Genevieve Jesudason, David
description	Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been linked with diabetic ketoacidosis (DKA). However, characteristics of "at-risk" patients are less well described. Clinical cases were collected from South Australia between December 2015 and March 2017. Key issues identified were that most patients did not recognize DKA, treating physicians often did not initially recognize DKA due to relative euglycemia, and effective treatment was delayed.
doi_str_mv	10.2337/dc17-1721
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2002220615</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2100381360</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-7bf26e86be77bf99ad76bf70236bbfcf478d9e44f21c874dae87e234169650a63</originalsourceid><addsrcrecordid>eNpdkc1O3DAUhS1UVAbogheoLHXTLtL6L3bMLpoOFHXULgbWkWPfFKOMPdgOEs_CyzajoVXV1T2L7x4d6UPogpLPjHP1xVmqKqoYPUILqnld1bVo3qAFoUJXtdbsBJ3m_EAIEaJp3qITpoUglLIFetlcr28Zvgn3vvclpqrNOVpvCji8mn6Nzxa23uKv3vRQ5vAdSjTWu5h9vsQt3sSp3ON2yiWZ0ZuAl6MP3poRL00GvIHkIWMT3L_MZhdDMQHilHHrniDN5OoJQsE_YvHD_F58DPkcHQ9mzPDu9Z6hu6vV7fJbtf55fbNs15UVVJRK9QOT0Mge1By1Nk7JflCEcdn3gx2EapwGIQZGbaOEM9AoYFxQqWVNjORn6OOhd5fi4wS5dFufLYzjYWLHCGGMEUnrGf3wH_oQpxTmdR2jhPCGcklm6tOBsinmnGDodslvTXruKOn2xrq9sW5vbGbfvzZO_RbcX_KPIv4b65CSDw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2100381360</pqid></control><display><type>article</type><title>SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications</title><source>EZB Electronic Journals Library</source><creator>Meyer, Emily J ; Gabb, Genevieve ; Jesudason, David</creator><creatorcontrib>Meyer, Emily J ; Gabb, Genevieve ; Jesudason, David</creatorcontrib><description>Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been linked with diabetic ketoacidosis (DKA). However, characteristics of "at-risk" patients are less well described. Clinical cases were collected from South Australia between December 2015 and March 2017. Key issues identified were that most patients did not recognize DKA, treating physicians often did not initially recognize DKA due to relative euglycemia, and effective treatment was delayed.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/dc17-1721</identifier><identifier>PMID: 29440112</identifier><language>eng</language><publisher>United States: American Diabetes Association</publisher><subject>Diabetes ; Diabetes mellitus ; Glucose ; Ketoacidosis ; Medical personnel ; Medical treatment ; Patients ; Physicians ; Sodium</subject><ispartof>Diabetes care, 2018-04, Vol.41 (4), p.e47-e49</ispartof><rights>Copyright American Diabetes Association Apr 1, 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-7bf26e86be77bf99ad76bf70236bbfcf478d9e44f21c874dae87e234169650a63</citedby><cites>FETCH-LOGICAL-c414t-7bf26e86be77bf99ad76bf70236bbfcf478d9e44f21c874dae87e234169650a63</cites><orcidid>0000-0002-7450-5808</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29440112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meyer, Emily J</creatorcontrib><creatorcontrib>Gabb, Genevieve</creatorcontrib><creatorcontrib>Jesudason, David</creatorcontrib><title>SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been linked with diabetic ketoacidosis (DKA). However, characteristics of "at-risk" patients are less well described. Clinical cases were collected from South Australia between December 2015 and March 2017. Key issues identified were that most patients did not recognize DKA, treating physicians often did not initially recognize DKA due to relative euglycemia, and effective treatment was delayed.</description><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Glucose</subject><subject>Ketoacidosis</subject><subject>Medical personnel</subject><subject>Medical treatment</subject><subject>Patients</subject><subject>Physicians</subject><subject>Sodium</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdkc1O3DAUhS1UVAbogheoLHXTLtL6L3bMLpoOFHXULgbWkWPfFKOMPdgOEs_CyzajoVXV1T2L7x4d6UPogpLPjHP1xVmqKqoYPUILqnld1bVo3qAFoUJXtdbsBJ3m_EAIEaJp3qITpoUglLIFetlcr28Zvgn3vvclpqrNOVpvCji8mn6Nzxa23uKv3vRQ5vAdSjTWu5h9vsQt3sSp3ON2yiWZ0ZuAl6MP3poRL00GvIHkIWMT3L_MZhdDMQHilHHrniDN5OoJQsE_YvHD_F58DPkcHQ9mzPDu9Z6hu6vV7fJbtf55fbNs15UVVJRK9QOT0Mge1By1Nk7JflCEcdn3gx2EapwGIQZGbaOEM9AoYFxQqWVNjORn6OOhd5fi4wS5dFufLYzjYWLHCGGMEUnrGf3wH_oQpxTmdR2jhPCGcklm6tOBsinmnGDodslvTXruKOn2xrq9sW5vbGbfvzZO_RbcX_KPIv4b65CSDw</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Meyer, Emily J</creator><creator>Gabb, Genevieve</creator><creator>Jesudason, David</creator><general>American Diabetes Association</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7450-5808</orcidid></search><sort><creationdate>20180401</creationdate><title>SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications</title><author>Meyer, Emily J ; Gabb, Genevieve ; Jesudason, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-7bf26e86be77bf99ad76bf70236bbfcf478d9e44f21c874dae87e234169650a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Glucose</topic><topic>Ketoacidosis</topic><topic>Medical personnel</topic><topic>Medical treatment</topic><topic>Patients</topic><topic>Physicians</topic><topic>Sodium</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meyer, Emily J</creatorcontrib><creatorcontrib>Gabb, Genevieve</creatorcontrib><creatorcontrib>Jesudason, David</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meyer, Emily J</au><au>Gabb, Genevieve</au><au>Jesudason, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2018-04-01</date><risdate>2018</risdate><volume>41</volume><issue>4</issue><spage>e47</spage><epage>e49</epage><pages>e47-e49</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><abstract>Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been linked with diabetic ketoacidosis (DKA). However, characteristics of "at-risk" patients are less well described. Clinical cases were collected from South Australia between December 2015 and March 2017. Key issues identified were that most patients did not recognize DKA, treating physicians often did not initially recognize DKA due to relative euglycemia, and effective treatment was delayed.</abstract><cop>United States</cop><pub>American Diabetes Association</pub><pmid>29440112</pmid><doi>10.2337/dc17-1721</doi><orcidid>https://orcid.org/0000-0002-7450-5808</orcidid><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0149-5992
ispartof	Diabetes care, 2018-04, Vol.41 (4), p.e47-e49
issn	0149-5992 1935-5548
language	eng
recordid	cdi_proquest_miscellaneous_2002220615
source	EZB Electronic Journals Library
subjects	Diabetes Diabetes mellitus Glucose Ketoacidosis Medical personnel Medical treatment Patients Physicians Sodium
title	SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T13%3A45%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SGLT2%20Inhibitor-Associated%20Euglycemic%20Diabetic%20Ketoacidosis:%20A%20South%20Australian%20Clinical%20Case%20Series%20and%20Australian%20Spontaneous%20Adverse%20Event%20Notifications&rft.jtitle=Diabetes%20care&rft.au=Meyer,%20Emily%20J&rft.date=2018-04-01&rft.volume=41&rft.issue=4&rft.spage=e47&rft.epage=e49&rft.pages=e47-e49&rft.issn=0149-5992&rft.eissn=1935-5548&rft_id=info:doi/10.2337/dc17-1721&rft_dat=%3Cproquest_cross%3E2100381360%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2100381360&rft_id=info:pmid/29440112&rfr_iscdi=true